MedPath
NMPA Approval

Dolutegravir Sodium, Abacavir Sulfate and Lamivudine Tablets

国药准字HJ20170345

May 23, 2022

H20170345

Drug Information

多替阿巴拉米片

绥美凯

片剂

每片含多替拉韦钠(以多替拉韦计)50mg、硫酸阿巴卡韦(以阿巴卡韦计)600mg和拉米夫定300mg

化学药品

May 23, 2022

May 22, 2027

Company Information

Applicant Company

ViiV Healthcare BV

Van Asch van Wijckstraat 55H, 3811 LP Amersfoort, Netherlands

Manufacturing Company

glaxo operations uk ltd (trading as glaxo wellcome operations)

Priory Street, Ware, Hertfordshire SG12 0DJ, United Kingdom

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

多替阿巴拉米片 - NMPA 批准文号 | MedPath